Navigation Links
New Cardioprotective Drug Could Provide Boost For Post-Bypass,Surgery Heart Health

SOMERSET, N.J., April 5, 2007-- Stent thrombosis, restenosis and lifelong prescriptions. Millions of patients have discovered that the drug-coated stents used as part of their heart operations may be having more of a detrimental effect on their health than medical experts have ever publicly acknowledged. Recent articles in medical journals suggest that unless patients who receive drug-eluting stents continue to take blood thinners, they could more than double their risk of heart attack or death.

This emerging safety controversy around drug-coated stents has some experts predicting a resurgence in heart bypass operations. The bypass operations, although more invasive and dangerous, are believed to have longer lasting benefits compared to stents.

"Doctors have been less inclined to recommend bypass surgery for their patients because of the risk associated with the procedure, most notably post-operative heart attacks," stated Dr. Bob Harrington of Duke Clinical Research Institute. "Unfortunately there are currently no approved drugs to lessen that risk."

One company that could improve bypass outcomes for patients is Medicure, Inc. The company has developed a cardio-protective drug known as MC-1 that in recent clinical trails cut the threat of post-operative heart attacks in bypass patients nearly in half. Medicure's MC-1 is currently in a late-stage clinical trial and if successful could lead to its approval for sale in the U.S.

"MC-1 has the opportunity to be the first drug available to help the hundreds of thousands of patients undergoing bypass surgery every year," says Medicure CEO Dr. Albert D. Friesen.

For more information on this topic go to: http://www.medicure.com/mc_1.html(http://www.medicure.com/mc_1.html) or call 888.435.2220

# # #


'"/>




Related medicine technology :

1. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
2. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
3. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
4. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. XTL Provides Update on Phase I Clinical Trial of XTL-2125
9. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
10. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
11. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):